Literature DB >> 15009002

Osteopenia, excess adiposity and hyperleptinaemia during 2 years of treatment for childhood acute lymphoblastic leukaemia without cranial irradiation.

J H Davies1, B A J Evans, E Jones, W D Evans, M E M Jenney, J W Gregory.   

Abstract

OBJECTIVE: Osteopenia and excess adiposity occur following treatment of childhood acute lymphoblastic leukaemia (ALL) and the use of cranial irradiation is thought to be a significant contributory factor. Hyperleptinaemia has also been demonstrated following cessation of treatment for childhood ALL. Therefore a prospective study was undertaken to evaluate serial changes in percentage bone mineral content (BMC), adiposity and serum leptin concentrations during 2 years of treatment of children with ALL with chemotherapy but without cranial irradiation. DESIGN AND PATIENT: Only patients treated using the MRC ALL 97/ALL 97 (modified 99) protocols for childhood ALL were eligible for entry into the study. A total of 14 patients (seven male, with a median age of 7.5 years (range 3.4-16.7 years) were recruited. Serial dual energy X-ray absorptiometry (DEXA) scanning was undertaken at diagnosis and during two years of treatment. Serum leptin concentrations were determined at the same time as the scans.
RESULTS: Reductions in %BMC were observed at the hip and lumbar spine by 12 months (P < 0.01) and remained low after 24 months of treatment. Subanalysis of %BMC measurements at the hip demonstrated a greater reduction in %BMC at the trochanteric region compared to the femoral neck. The percentage corrected fat mass increased from 6 months whereas the body mass index (BMI) standard deviation score (SDS) was increased after 24 months of treatment (P < 0.05). Serum leptin concentrations increased following 24 months of therapy (P < 0.05).
CONCLUSIONS: Children treated for ALL with contemporary regimens have a predisposition to osteopenia, excess adiposity and hyperleptinaemia during treatment without cranial irradiation administration. We speculate that in addition to glucocorticoid administration, leptin resistance may account in part for these observations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009002     DOI: 10.1111/j.1365-2265.2003.01986.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

Review 1.  Growth patterns during and after treatment in patients with pediatric ALL: A meta-analysis.

Authors:  Fang Fang Zhang; Shanshan Liu; Mei Chung; Michael J Kelly
Journal:  Pediatr Blood Cancer       Date:  2015-03-24       Impact factor: 3.167

2.  Bone mineral density among long-term survivors of childhood acute lymphoblastic leukemia: results from the St. Jude Lifetime Cohort Study.

Authors:  J G Gurney; S C Kaste; W Liu; D K Srivastava; W Chemaitilly; K K Ness; J Q Lanctot; R P Ojha; K A Nottage; C L Wilson; Z Li; L L Robison; M M Hudson
Journal:  Pediatr Blood Cancer       Date:  2014-02-28       Impact factor: 3.167

Review 3.  Obesity and Metabolic Syndrome Among Adult Survivors of Childhood Leukemia.

Authors:  Todd M Gibson; Matthew J Ehrhardt; Kirsten K Ness
Journal:  Curr Treat Options Oncol       Date:  2016-04

4.  Acute lymphoblastic leukemia and obesity: increased energy intake or decreased physical activity?

Authors:  H Jansen; A Postma; R P Stolk; W A Kamps
Journal:  Support Care Cancer       Date:  2008-11-07       Impact factor: 3.603

5.  Visfatin is a positive predictor of bone mineral density in young survivors of acute lymphocytic leukemia.

Authors:  Adriana Aparecida Siviero-Miachon; Angela Maria Spinola-Castro; Maria Lucia de Martino Lee; Antonio Ramos Calixto; Bruno Geloneze; Marise Lazaretti-Castro; Gil Guerra-Junior
Journal:  J Bone Miner Metab       Date:  2015-12-11       Impact factor: 2.626

Review 6.  Obesity in patients with acute lymphoblastic leukemia in childhood.

Authors:  Lorenzo Iughetti; Patrizia Bruzzi; Barbara Predieri; Paolo Paolucci
Journal:  Ital J Pediatr       Date:  2012-01-27       Impact factor: 2.638

7.  Body mass index and annual increase of body mass index in long-term childhood cancer survivors; relationship to treatment.

Authors:  Cornelia A J Brouwer; Jourik A Gietema; Judith M Vonk; W J E Tissing; Hendrika M Boezen; Nynke Zwart; Aleida Postma
Journal:  Support Care Cancer       Date:  2011-01-15       Impact factor: 3.603

Review 8.  Bone morbidity in childhood leukemia: epidemiology, mechanisms, diagnosis, and treatment.

Authors:  Sogol Mostoufi-Moab; Jacqueline Halton
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

9.  Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate.

Authors:  Chia-Ming Fan; Bruce K Foster; Susanta K Hui; Cory J Xian
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  Bone mineral density deficits in childhood cancer survivors: Pathophysiology, prevalence, screening, and management.

Authors:  Min Jae Kang; Jung Sub Lim
Journal:  Korean J Pediatr       Date:  2013-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.